The First Affiliated Hospital of Anhui Medical University
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China44 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, gonadal disorder, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, squamous cell carcinoma, transitional cell carcinoma, urothelial carcinoma, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT04152499 | |
| Sintilimab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Locally Advanced Gastroesophageal Junction Cancer | gastroesophageal junction adenocarcinoma | Not yet recruiting | Not applicable | 2026-10-05 | NCT07859410 | |
| Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery | Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, cardiovascular disorder, ischemia reperfusion injury, vascular disorder | Recruiting | Not applicable | 2026-09-16 | NCT07383909 | |
| Renal Oxygenation-Guided AKI Reduction Trial | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, acute kidney injury, kidney disorder, kidney failure, urinary system disorder | Not yet recruiting | Not applicable | 2026-09-14 | NCT07816640 | |
| Efficacy and Safety of Colchicine After PCI | cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-03 | NCT06472908 | |
| A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Phase 3 | 2026-08-31 | NCT07795346 | |
| Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma | Camrelizumab; Locally Advanced Esophageal Squamous Cell Carcinoma; Neoadjuvant Therapy | Recruiting | Phase 2 | 2026-08-26 | NCT07787273 | |
| A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 3 | 2026-07-30 | NCT04194775 | |
| A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Recruiting | Phase 1 / Phase 2 | 2026-07-29 | NCT07327229 | |
| PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-07-29 | NCT06419621 | |
| RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-07-14 | NCT07416474 | |
| A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Phase 3 | 2026-07-08 | NCT07282353 | |
| Study on Early Visual Dysfunction in Patients With Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Enrolling by invitation | Not stated | 2026-07-01 | NCT07679776 | |
| CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic disease | Not yet recruiting | Early phase 1 | 2026-06-18 | NCT07657780 | |
| A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-06-17 | NCT07164170 | |
| A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-16 | NCT07547553 | |
| Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-06-10 | NCT07379047 | |
| A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H) | Advanced Solid Tumors | Not yet recruiting | Phase 1 | 2026-06-03 | NCT07593144 | |
| A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus | Skin and Connective Tissue Diseases, connective tissue disorder, cutaneous lupus erythematosus, discoid lupus erythematosus, skin disorder | Not yet recruiting | Phase 2 | 2026-04-30 | NCT07557927 | |
| A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-04-13 | NCT06564324 | |
| The Chinese Familial Alzheimer's Network | Alzheimer disease, Familial Alzheimer Disease (FAD), brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Not stated | 2026-03-23 | NCT03657732 | |
| China Cognition and Aging Study | Alzheimer Disease, Late Onset, Alzheimer disease, Arterial Occlusive Diseases, Cognition Disorders, Cognitive Dysfunction, Familial Alzheimer Disease (FAD), Leukoencephalopathies, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, cognitive disorder, dementia, intracranial arterial disease, intracranial arteriosclerosis, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy, vascular dementia, vascular disorder | Recruiting | Not stated | 2026-03-23 | NCT03653156 | |
| A Study YL201 in Patients With Selected Advanced Solid Tumors | Advanced Solid Tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-12 | NCT06057922 | |
| A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Urogenital Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, autoimmune disease, cardiovascular disorder, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, necrotizing vasculitis, nephritis, nervous system disorder, neuromuscular disease, skin disorder, skin vascular disease, systemic lupus erythematosus, systemic sclerosis, urinary system disorder, vascular disorder, vasculitis | Recruiting | Phase 1 | 2026-03-02 | NCT07104721 | |
| CS-121 APOC3 Base Editing in FCS | Digestive System Diseases, Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, familial lipoprotein lipase deficiency, hyperlipidemia, hypertriglyceridemia, metabolic disease, pancreas disorder, pancreatitis | Recruiting | Early phase 1 | 2026-02-11 | NCT07176923 |